Table 5.
Comparison of postoperative adverse events among the prostate volume groups according to the Clavien-Dindo classification. The following adverse events and consecutive managements is demonstrated in the table
| Adverse events | Group 1 ePV <40 mL (n = 67) | Group 2 ePV 40–80 mL (n = 200) | Group 3 ePV ≥80 mL (n = 131) | P |
|---|---|---|---|---|
| Overall AEs, n (%) | 10 (14.9%) | 32 (16.0%) | 15 (11.5%) | 0.507 |
| Clavien-Dindo I | 7 (70.0%) | 16 (50.0%) | 4 (26.7%) | |
| Clavien-Dindo II | 0 (0.0%) | 5 (15.6%) | 2 (13.3%) | 0.199 |
| Clavien-Dindo III | 3 (30.0%) | 11 (34.4%) | 9 (60.0%) |
| Clavien-Dindo grade | Adverse events | Management |
|---|---|---|
| I | Gross hematuria ± urinary retention due to blood clot (n = 21) | Foley catheter insertion and bladder irrigation |
| Acute urinary retention without hematuria (n = 6) | Foley catheter insertion | |
| II | Epididymitis (n = 2) | PO medication |
| Prostatitis (n = 1) | PO medication | |
| Acute pyelonephritis (n = 1) | IV antibiotics | |
| Other UTI (n = 1) | IV antibiotics | |
| Urethral stricture (n = 1) | sounding | |
| Gross hematuria (n = 1) | PO Tranexamic acid | |
| III | Gross hematuria ± urinary retention due to blood clot (n = 11) | Transurethral fulguration under anesthesia |
| Urethral stricture (n = 2) | Urethral dilation under anesthesia | |
| Bladder neck contraction (n = 7) | Transurethral incision of bladder neck | |
| Bladder stone (n = 3) | Cystolitholapaxy under anesthesia |
ePV, estimated prostate volume; AE, adverse event.